BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GP
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ebola Virus Disease
Conditions
Ebola Virus Disease, COVID-19
Trial Timeline
Oct 1, 2024 → May 1, 2025
NCT ID
NCT06587503About BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GP
BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GP is a approved stage product being developed by Merck for Ebola Virus Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06587503. Target conditions include Ebola Virus Disease, COVID-19.
What happened to similar drugs?
1 of 3 similar drugs in Ebola Virus Disease were approved
Approved (1) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06587503 | Approved | Recruiting |
Competing Products
20 competing products in Ebola Virus Disease